{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T16:13:17Z","timestamp":1772727197479,"version":"3.50.1"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T00:00:00Z","timestamp":1642118400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["JP21K08785"],"award-info":[{"award-number":["JP21K08785"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Bladder cancer is one of the most common cancers worldwide. The anti-programmed cell death protein 1 (PD-1) antibody pembrolizumab, which is an immune checkpoint inhibitor (ICI), has improved survival in bladder cancer. We report a case of bladder cancer that had a high antitumor effect with anti-programmed cell death PD-1 antibody pembrolizumab, an ICI, but asthma occurred an immune-related adverse event (irAE).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 70-year-old female patient was diagnosed as unresectable bladder cancer who was indicated for ICI treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>After ICI administration as a treatment for bladder cancer, the patient had a grade 3 asthma attack. Cytotoxic T lymphocyte antigen 4 (CTLA-4) in CD4<jats:sup>+<\/jats:sup> FOX3<jats:sup>+<\/jats:sup> T cells was upregulated in the early phase before the development of asthma attacks. Moreover, T-cell immunoglobulin and mucin domain 3 (TIM-3) was upregulated in all memory T cells among CD4<jats:sup>+<\/jats:sup> T cells. However, no change in the expression of TIM-3 was observed in any CD8<jats:sup>+<\/jats:sup> T-cell subtype. In contrast, the proportion of CD161<jats:sup>-<\/jats:sup> T helper 17 cell (Th17) cells increased.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The patient was treated with betamethasone, montelukast, salbutamol nebulization, and a combination of salmeterol (50\u200a\u03bcg) and fluticasone (500\u200a\u03bcg) (SFC).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The patient's wheezing resolved, and her peak flow rate reached 100% of the predicted value; therefore, the patient continued treatment with SFC and montelukast and was discharged from the hospital.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Increases in CTLA-4 and TIM-3 expression in CD4<jats:sup>+<\/jats:sup> T cells (not CD8<jats:sup>+<\/jats:sup>), as well as an increase in Th17 cells, may reflect asthma-related inflammation activity. Immune-related adverse events during immune checkpoint inhibitor administration may be predictive markers of antitumor efficacy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000028339","type":"journal-article","created":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T13:05:21Z","timestamp":1642165521000},"page":"e28339","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["A case of bronchial asthma as an immune-related adverse event of pembrolizumab treatment for bladder cancer"],"prefix":"10.1097","volume":"101","author":[{"given":"Kazuyuki","family":"Hamada","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, Showa University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Yoshimura","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, Showa University School of Medicine, Tokyo, Japan"},{"name":"Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Oshinomi","sequence":"additional","affiliation":[{"name":"Department of Urology, Showa University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Hirasawa","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, Showa University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotsugu","family":"Ariizumi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, Showa University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryotaro","family":"Ohkuma","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, Showa University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Midori","family":"Shida","sequence":"additional","affiliation":[{"name":"Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaro","family":"Kubota","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, Showa University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroto","family":"Matsui","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, Showa University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Ishiguro","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, Showa University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiko","family":"Sambe","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroo","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, Showa University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Horiike","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, Showa University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Wada","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, Showa University School of Medicine, Tokyo, Japan"},{"name":"Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanju","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"Division of Physiology and Pathology, Department of Pharmacology, Toxicology and Therapeutics, Showa University School of Pharmacy, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Urology, Showa University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Tsunoda","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, Showa University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,1,14]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1093\/annonc\/mdx455","article-title":"Nivolumab-induced asthma in a patient with non-small-cell lung cancer","volume":"28","author":"Maeno","year":"2017","journal-title":"Ann Oncol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.jtho.2018.09.002","article-title":"Fatal airway inflammation induced by pembrolizumab in a patient with NSCLC","volume":"14","author":"Ogawa","year":"2019","journal-title":"J Thorac Oncol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000504968","article-title":"Immunotherapy-induced airway disease: a new pattern of lung toxicity of immune checkpoint inhibitors","volume":"99","author":"Mitropoulou","year":"2020","journal-title":"Respiration"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.jtho.2017.08.022","article-title":"Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with nivolumab: a prospective cohort study","volume":"12","author":"Teraoka","year":"2017","journal-title":"J Thorac Oncol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/annonc\/mdx686","article-title":"Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy","volume":"29","author":"Rotte","year":"2018","journal-title":"Ann Oncol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1159\/000250438","article-title":"Th17 immunity in patients with allergic asthma","volume":"151","author":"Zhao","year":"2010","journal-title":"Int Arch Allergy Immunol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028339","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:24:34Z","timestamp":1746332674000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028339"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2022,1,14]]},"references-count":8,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000028339","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,14]]},"assertion":[{"value":"2021-08-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}